Email Updates

You are here

DREAM-01

Status
Ongoing
Phase
I
Objective

DREAM-01 is an early phase 1, open label, dose-escalation and variable osmolarity study to compare the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of 3 formulations of a tenofovir (TFV) enema. 

Prevention Option(s)
Microbicides
Multipurpose Prevention Technologies
Study Design
Non-randomized
Open label
October 2016
November 2019
Enrollment
21
18
Years
Population
Men
Sites

UCLA Center for HIV Prevention Research

Los Angeles
United States of America

College of Medicine John Hopkins University Clinical Research Site

Blantyre
Malawi

University of Pittsburgh CRS

Pittsburgh, Pennsylvania
United States of America